Gonorrhea Therapeutics Market Size and Forecast 2024

1. Downloaded from: justpaste.it/6g7gs Gonorrhea Therapeutics Market Latest Research Report and Growth to 2024 The gonorrhea therapeutics market size has the potential to grow by USD 350.90 million during 2020-2024, and the market’s growth momentum will accelerate during the forecast period. Get Sample of the Report: https://www.technavio.com/talk-to-us? report=IRTNTR44632&type=sample&src=report This report provides a detailed analysis of the market by therapy (monotherapy and combination therapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Bristol-Myers Squibb Co., Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Merck & Co. Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Market Competitive Analysis The gonorrhea therapeutics market is fragmented with the presence of both global and regional vendors. Vendors are partnering with research organizations and hospitals for R&D and are participating in various scientific conferences to showcase their products. Such efforts will provide long-term development opportunities to them. The key vendors in the global gonorrhea therapeutics market are focusing on product approvals and M&A to gain a competitive edge in the market. Inorganic growth strategies, robust R&D, and pricing strategies will increase competition among these vendors. AstraZeneca Plc, Bristol-Myers Squibb Co., and Cipla Inc. are some of the major market participants. Although the growing use of new diagnostic tests will offer immense growth opportunities, the emergence of antibiotic-resistant gonococcal strain will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. To help clients improve their market position, this gonorrhea therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this gonorrhea therapeutics market analysis report also provides information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities. Gonorrhea Therapeutics Market: Key Drivers and Trends Technavio’s research analysis on the global gonorrhea therapeutics market has identified that the growing use of new diagnostic tests will be one of the major factors that will have a positive impact on the market growth in the coming years. The rising incidence of gonorrhea has resulted in the emergence of new diagnostic tests such as nucleic acid amplification tests (NAATs). This allows an early diagnostic screening to avoid the spread of the

2. infection to the upper genital tract. People suffering from gonorrhea are advised to take the appropriate antibiotics for gonorrhea and repeat the gonorrhea test after three to six months. Traditional culture, nucleic acid hybridization, and NAATs are a few of the diagnostic tests that confirm the presence of Neisseria gonorrhoeae. NAATs are highly preferred over traditional cultures since they show improved sensitivity and selectivity for Neisseria gonorrhoeae at rectal and oropharyngeal sites in men. The availability of highly sensitive and selective testing modalities drives the demand for gonorrhea therapeutics, in turn, propelling market growth. Our market research analysts predict that this global market will grow at a CAGR of almost 5% during the forecast period One of the key trends that will gain traction in the gonorrhea therapeutics market during the estimated period is the rise in government initiatives to combat antibiotic resistance. According to the Centers for Disease Control and Prevention (CDC), the US government released a plan to ‘Combat Antibiotic-Resistant Bacteria’ (CARB). This helps in the prevention, detection, and control of antibiotic resistance. Consequently, this control of antibiotic resistance in gonorrheal infection will increase patient adherence towards antibiotic therapy. Gonorrhea Therapeutics Market: Key Highlights of the Report for 2020-2024 CAGR of the market during the forecast period 2020-2024 Detailed information on factors that will drive gonorrhea therapeutics market growth during the next five years Precise estimation of the gonorrhea therapeutics market size and its contribution to the parent market Accurate predictions on upcoming trends and changes in consumer behavior The growth of the gonorrhea therapeutics industry across Asia, Europe, North America, and ROW A thorough analysis of the market’s competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of gonorrhea therapeutics market vendors